-
1.发明公开VERWENDUNG VON GESTAGENEN IN KOMBINATION MIT (6S)5-METHYLTETRAHYDROFOLAT ZUR THERAPIE DER ENDOMETRIOSE MIT GLEICHZEITIGER VERMINDERUNG VON THERAPIE-NEBENWIRKUNGEN SOWIE DER VERMINDERUNG DES RISIKOS ANGEBORENER FEHLBILDUNGEN BEI EINTRITT EINER GRAVIDITÄT 审中-公开孕激素的IN与还原剂先天性畸形的危险妊娠入院治疗和副作用同时减少子宫内膜异位症（6S）-5-甲基四氢叶酸联合治疗中使用
公开(公告)号：EP2194978A1
公开(公告)日：2010-06-16
申请号：EP08785200.0
申请日：2008-07-30
发明人： SEITZ, Christian , WASSERFALL, Annemarie , DIEFENBACH, Konstanze , KING, Kristina , ZIMMERMANN, Holger
IPC分类号： A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61P15/02 , A61P15/12 , A61P15/18 , A61P19/10 , A61P43/00
CPC分类号： A61K45/06 , A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61K2300/00
摘要： Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations for the therapy of endometrioses with simultaneous reduction of therapy side effects, such as the negative impact on bone density/bone metabolism and the risk for osteoporosis, and in the event of pregnancy, the reduction of the risk on congenital malformations, such as neural tube defects, cheilognathopalatoschisis and complications during pregnancy, such as the detachment of the placenta and premature birth. The invention is suitable for long-term use.
-
公开(公告)号：EP2040683A1
公开(公告)日：2009-04-01
申请号：EP07764936.6
申请日：2007-06-29
发明人： KING, Kristina
IPC分类号： A61K9/20 , A61K31/585 , A61K31/567 , A61K31/525 , A61P15/18
CPC分类号： A61K9/2054 , A61K9/2018
摘要： The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.
-
搜索结果
2 条记录 (耗时 0.011 秒)
